SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants

PURPOSE: Patients with antibody deficiencies often receive maintenance treatment with donor plasma-derived immunoglobulin (Ig) preparations to decrease the incidence and severity of infections. We have previously shown that IgG antibodies to the original SARS-CoV-2 strain were not consistently prese...

Descripción completa

Detalles Bibliográficos
Autores principales: Lindahl, Hannes, Chen, Puran, Åberg, Mikael, Ljunggren, Hans-Gustaf, Buggert, Marcus, Aleman, Soo, Smith, C. I. Edvard, Bergman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102687/
https://www.ncbi.nlm.nih.gov/pubmed/37058198
http://dx.doi.org/10.1007/s10875-023-01486-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10102687/
https://www.ncbi.nlm.nih.gov/pubmed/37058198
http://dx.doi.org/10.1007/s10875-023-01486-8

Ejemplares similares